Tin tức & Cập nhật

Chỉ hiển thị Multimedia
How common is viral burden rebound in hospitalized COVID-19 patients with or without oral antiviral treatment?

How common is viral burden rebound in hospitalized COVID-19 patients with or without oral antiviral treatment?

03 Mar 2023 bởiSarah Cheung

A real-world study during Hong Kong’s Omicron BA.2.2 wave has shown that viral burden rebound is uncommon in hospitalized COVID-19 patients not requiring supplemental oxygen on admission, regardless of whether they were treated with nirmatrelvir/ritonavir or molnupiravir. However, immunocompromised patients, regardless of oral antiviral use, are more likely to have viral burden rebound.

03 Mar 2023
Mirabegron, vibegron equally effective in postmenopausal women with OAB

Mirabegron, vibegron equally effective in postmenopausal women with OAB

03 Mar 2023

Mirabegron appears to be as good as vibegron in the treatment of overactive bladder (OAB) in postmenopausal women, with both drugs helping improve symptoms and the parameters of voiding diary, according to a study.

03 Mar 2023
HPV infection ups CVD risk, but not in vaccinated women

HPV infection ups CVD risk, but not in vaccinated women

02 Mar 2023

Human papillomavirus (HPV) infection appears to be a risk factor for cardiovascular diseases (CVDs), suggests a recent study. However, women vaccinated against HPV are protected against such risk.

02 Mar 2023
Which factors shape decisions to withdraw life support in stroke patients?

Which factors shape decisions to withdraw life support in stroke patients?

02 Mar 2023 bởiStephen Padilla

The decision to withdraw life-sustaining therapy (WLST) among acute hospitalized stroke patients is determined by several factors, including age, race, level of consciousness, state region, insurance status, ambulation status at baseline, and stroke centre type, suggests a study presented at ISC 2023.

02 Mar 2023
Final PROpel data confirm OS advantage with abiraterone plus olaparib

Final PROpel data confirm OS advantage with abiraterone plus olaparib

01 Mar 2023 bởiJairia Dela Cruz

The combination of olaparib plus abiraterone in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) appears to show a consistent trend toward overall survival (OS) benefit, according to the results of the final prespecified analysis of the phase III PROpel study presented at ASCO GU 2023.

01 Mar 2023
Use of biomarkers, biologics ups success rate of clinical trials in gastric cancer

Use of biomarkers, biologics ups success rate of clinical trials in gastric cancer

01 Mar 2023

Success rates of clinical trials in gastric cancer tend to improve with the use of implementing biomarkers, receptor-targeted therapies, and biologics in clinical development, suggests a recent study.

01 Mar 2023